B-cell Lymphoma vs. T-cell Lymphoma: What Are The Differences Between The Two?

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B and Why T?

To begin, don't attach too much significance to the letters B and T; the people who assigned them didn't attach much, so you shouldn't either.

In fact, B-cells don't even get their name from research into human anatomy. They get it from research into bird anatomy, but the B isn't for "birds"; the B is for the site in birds where this specific type of blood cell matures, called the bursa of fabricius. Fortunately, in humans and many other mammals, B-cells mature in the bone marrow, allowing the B to continue to make sense.

Meanwhile, T-cells do get their name from human anatomy. Like in B-cells, the letter comes from the site where they mature; in this case, it is the thymus.

Prognoses and Incidence

The prognoses of most T-cell lymphomas are not that great; they're worse than the prognoses in most B-cell lymphomas.

B-cell five-year relative survival rates from the SEER statistics:

  • Localized disease: 82.3 percent
  • Regional disease: 75.2 percent
  • Metastatic disease: 63.6 percent

T-cell five-year relative survival rates from the SEER statistics:

  • Localized disease: 84.5 percent
  • Regional disease: 57.4 percent
  • Metastatic disease: 38.6 percent

As seen above, when caught early, the five-year relative survival rates are pretty equal, but when the disease has spread from the primary site, even just to regional areas, the prognosis begins to slip. When the disease is advanced, the relative survival rate nearly drops by half.

This is generally the case, not because T-cell lymphomas are so difficult to treat, but because T-cell lymphomas are so rare, and are therefore not studied as frequently as their B-cell counterparts. Approximately 85 percent of all non-Hodgkin's lymphomas diagnosed in the United States each year are of B-cell origin, leaving just 15 percent of diagnoses to be of T-cell origin.

Diagnosis

Finally, it should be added that B-cell lymphomas are much easier for pathologists to diagnose. Accurately diagnosing T-cell lymphomas, on the other hand, is extremely difficult, so any diagnosis of T-cell lymphoma should prompt a second opinion from a qualified blood pathologist.

You can read more about B-cell lymphomas by clicking here.

You can read more about T-cell lymphomas by clicking here.

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap